Results 71 to 80 of about 1,261,156 (366)

Non-parametric Bayesian mixture model to study adverse events of COVID-19 vaccines [PDF]

arXiv, 2023
The vaccine adverse event reporting system (VAERS) is a vital resource for post-licensure vaccine safety monitoring and has played a key role in assessing the safety of COVID-19 vaccines. However it is difficult to properly identify rare adverse events (AEs) associated with vaccines due to small or zero counts.
arxiv  

Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data [PDF]

PLOS ONE 11(4) (2016) e0151470, 2015
Understanding the causes and patient impacts of surgical adverse events will help improve systems and operational practices to avoid incidents in the future. We analyzed the adverse events data related to robotic systems and instruments used in minimally invasive surgery, reported to the U.S. FDA MAUDE database from January 2000 to December 2013.
arxiv   +1 more source

Extracting postmarketing adverse events from safety reports in the vaccine adverse event reporting system (VAERS) using deep learning

J. Am. Medical Informatics Assoc., 2021
OBJECTIVE Automated analysis of vaccine postmarketing surveillance narrative reports is important to understand the progression of rare but severe vaccine adverse events (AEs).
Jingcheng Du, Yang Xiang, M. Sankaranarayanapillai, Meng Zhang, Jingqi Wang, Yuqi Si, Huy Anh Pham, Hua Xu, Yong Chen, Cui Tao   +9 more
semanticscholar   +1 more source

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System

Cancers, 2021
Simple Summary This post-marketing research addressed the role of cyclin-dependent kinase 4/6 inhibitors, relatively new anticancer drugs approved for advanced breast cancer in cancer-associated thrombosis.
E. Raschi, M. Fusaroli, A. Ardizzoni, E. Poluzzi, F. De Ponti   +4 more
semanticscholar   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Suffering from Vaccines or from Government? : Partisan Bias in COVID-19 Vaccine Adverse Events Coverage [PDF]

arXiv, 2022
Vaccine adverse events have been presumed to be a relatively objective measure that is immune to political polarization. The real-world data, however, shows the correlation between presidential disapproval ratings and the subjective severity of adverse events.
arxiv  

A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data

Scientific Reports, 2021
Proton pump inhibitor (PPI) was widely used around the world. Studies suggested conflicting results between PPI treatment and dementia event. This study examined the association between six PPI agents and dementia event by mining the US FDA Adverse Event
Bin Wu, Qiaozhi Hu, F. Tian, Fengbo Wu, Yuwen Li, Ting Xu   +5 more
semanticscholar   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

Cancers, 2020
Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML), can be associated to cardiovascular (CV) adverse events (AEs).
S. Cirmi, Asmae El Abd, L. Létinier, M. Navarra, F. Salvo   +4 more
semanticscholar   +1 more source

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Frontiers in Pharmacology, 2022
Esketamine was approved for the treatment of treatment-resistant depression in 2019. After the approval of esketamine, numerous concerns have been raised regarding its long-term safety and tolerability.
Haoning Guo, Bin Wang, Shuying Yuan, Silin Wu, Jing Liu, Miaoquan He, Ji-sheng Wang   +6 more
semanticscholar   +1 more source